BioCentury
ARTICLE | Clinical News

Actelion reports walking improvement for macitentan

October 25, 2012 12:29 AM UTC

Actelion Ltd. (SIX:ATLN) said oral Opsumit macitentan led to a significant baseline-adjusted, placebo-corrected mean increase in 6-minute walk distance (6MWD) of 23 meters at six months in the Phase III SERAPHIN to treat pulmonary arterial hypertension (PAH) (p=0.007). In patients with WHO functional class III/IV PAH at baseline, Opsumit led to a placebo-corrected mean increase in 6MWD of 37 meters (p=0.009). Additionally, Opsumit reduced the risk of all-cause mortality by 36% vs. placebo, but the difference was not significant (p=0.2037). Patients were allowed to receive background PAH therapy consisting of phosphodiesterase-5 (PDE-5) inhibitors or oral/inhaled prostanoids throughout the study. Actelion was off CHF0.04 to CHF45.28 on Wednesday. ...